Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.

MLA

Gueneau, Pauline, et al. “Efficacy, Safety, and Cost of Pomalidomide in Relapsed and Refractory Multiple Myeloma.” European Journal of Haematology, vol. 100, no. 5, May 2018, pp. 518–25. EBSCOhost, https://doi.org/10.1111/ejh.13039.

APA

Gueneau, P., Chretien, M., Cransac, M. A., Aho, L. S., Lafon, I., Favennec, C., Guy, J., Caillot, D., & Boulin, M. (2018). Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. European Journal of Haematology, 100(5), 518–525. https://doi.org/10.1111/ejh.13039

Chicago

Gueneau, Pauline, Marie‐Lorraine Chretien, Miet, Amelie Cransac, Ludwig Serge Aho, Ingrid Lafon, Camille Favennec, Julien Guy, Denis Caillot, and Mathieu Boulin. 2018. “Efficacy, Safety, and Cost of Pomalidomide in Relapsed and Refractory Multiple Myeloma.” European Journal of Haematology 100 (5): 518–25. doi:10.1111/ejh.13039.